Seer announces the launch of a population-level study on biomakers
Seer (SEER) announced the launch of a population-level study aimed at identifying novel blood-based biomarkers that could lead to cancer diagnostics for young adults in their 20s and 30s. Relying on Seer's newly launched Proteograph ONE Assay and SP200 Automation Instrument along with the Thermo Scientific Orbitrap Astral mass spectrometer, this is the first large-scale plasma proteomics initiative of its kind to leverage mass spectrometry and AI-driven analytics to enhance early cancer detection and improve patient outcomes. Seer's latest platform advances will allow deep, unbiased proteomic analysis of 20,000 plasma samples in less time and cost than before.
Confident Investing Starts Here:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 days ago
- Yahoo
Otto Aviation Standardizes on Galorath's AI-Powered Estimation Platform to Drive Price-to-Win Strategies Across Sustainable Aerospace Initiatives
LONG BEACH, Calif., June 3, 2025 /PRNewswire/ -- Galorath, the premier AI-powered estimation platform provider for cost, schedule, and risk analysis, today announced that Otto Aviation (Otto) is standardizing on its flagship SEER® platform. Otto will leverage the platform's structured operational intelligence to anticipate costs and streamline production efforts as it works to create the future of sustainable air travel through paradigm-shifting design, performance, and economics. In the evolving supply chain landscape, Otto will rely heavily on SEER for Manufacturing (SEER-MFG™) and SEER-3D predictive data modules to develop accurate and efficient manufacturing and assembly costs. SEER allows Otto to build parametric estimates and risk profiles by leveraging historical insights, improving planning precision. The Otto team can interact directly with its proprietary and Galorath-sourced historical data. This simplifies WBS generation and unlocks actionable, data-backed insights earlier in the process. "As we enter the next phase of aircraft development, time-to-market, quality control, and resource accuracy are critical to our success," said Obi K. Ndu, PhD, Chief Information and Digital Officer, Otto Aviation. "Integrating Galorath's SEER platform into workflows ensures we have the right tools to combat economy-driven constraints and focus on cost, outcome predictions, and meeting design requirements, keeping us ahead of the curve with a strategic advantage." Guided by a team of experienced and accomplished aerospace leaders, Otto is ushering in a new era of transonic super-laminar (TSL) aircraft that is more operationally efficient and environmentally friendly. As Otto approaches design initiatives for customers, the SEER-MFG data module empowers Otto with accurate estimation, predictive analytics, risk analysis tools, labor and resource forecasting, and material and production modeling. As designs evolve, the SEER 3D data module allows Otto to update and refresh estimates by generating detailed costs from any CAD system and evaluating cost-saving alternatives. "Delivering sustainable flight innovation demands precision, flexibility, and rigorous control. Galorath's AI-powered estimation platform brings structure to that complexity," said Charles Orlando, Chief Strategy Officer at Galorath. "The complexities of navigating quality control issues, new regulations, and persistent supply chain constraints require a sophisticated solution. Galorath's AI-powered estimation platform delivers structured cost, schedule, and risk analysis through a unified environment that scales across Otto team members and designs." SEER AI-Powered Estimation and Planning Built on Galorath's trusted SEER modeling framework, the platform combines analytical depth with intuitive access. SEER's core modeling framework is refined over decades of complex program execution that addresses the needs of cost, schedule, labor, risk, should-cost, and price-to-win estimation and analysis for hardware, software, manufacturing, and information technology (IT). The platform's operational intelligence layer, SEERai™, is integrated throughout the experience. It enables natural interaction, embedded guidance, and intelligent automation – reducing cycle time, improving alignment, and unlocking knowledge trapped in documents, processes, and expert memory. For more information about the SEER platform, visit About Otto Aviation Otto is creating ultra-efficient, sustainable flight through paradigm-shifting technologies. Otto distinguishes itself as an aerospace trailblazer through its selection to participate in the OECIF-resourced, DARPA-led Energy Web Aircraft program, showcasing a strong commitment to innovation. For more information, visit About Galorath Incorporated Galorath delivers an AI-powered business operations platform grounded in decades of real-world cost, schedule, and risk validation for operations, supply chains, and manufacturing. Their flagship SEER® platform is trusted by industry giants in high-stakes environments, like Accenture, NASA, Boeing, the U.S. Department of Defense, and BAE Systems (EU), among others. Built on Galorath's trusted SEER modeling framework, the platform combines analytical depth with intuitive access to accelerate time to market, enhance project predictability and visibility, and ensure project costs are on track. For more information, visit SEER is a registered trademark of Galorath Incorporated. SEER-MFG and SEERai are trademarks of Galorath Incorporated. All other trademarks are the property of their respective owners. This press release may contain forward-looking statements that involve risks and uncertainties, including statements regarding the future financial performance, business strategies, market conditions, and product development plans of the companies mentioned. Actual results may differ materially from those expressed or implied in these forward-looking statements due to various factors, including those discussed in filings with the Securities and Exchange Commission. The companies mentioned here undertake no obligation to update any forward-looking statements contained herein, whether due to new information, future events, or otherwise. View original content to download multimedia: SOURCE Galorath Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
5 days ago
- Business Insider
Seer announces the launch of a population-level study on biomakers
Seer (SEER) announced the launch of a population-level study aimed at identifying novel blood-based biomarkers that could lead to cancer diagnostics for young adults in their 20s and 30s. Relying on Seer's newly launched Proteograph ONE Assay and SP200 Automation Instrument along with the Thermo Scientific Orbitrap Astral mass spectrometer, this is the first large-scale plasma proteomics initiative of its kind to leverage mass spectrometry and AI-driven analytics to enhance early cancer detection and improve patient outcomes. Seer's latest platform advances will allow deep, unbiased proteomic analysis of 20,000 plasma samples in less time and cost than before. Confident Investing Starts Here:
Business Upturn
6 days ago
- Business Upturn
Seer's Proteograph Platform Enables Unprecedented 20,000-Sample Proteomics Study with Korea University to Develop AI-Driven Diagnostics for Cancers in Young Adults
First-of-its-kind study will use Seer's next-generation workflow to identify early-onset cancer biomarkers and power deep, unbiased mass spectrometry-based proteomics Seer's new Proteograph ONE Assay to accelerate analysis and reduce costs, making large-scale studies feasible REDWOOD CITY, Calif., June 01, 2025 (GLOBE NEWSWIRE) — Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, and Korea University, a leading research institution committed to innovation and global impact, today announced the launch of a population-level study aimed at identifying novel blood-based biomarkers that could lead to cancer diagnostics for young adults in their 20s and 30s. Relying on Seer's newly launched Proteograph® ONE Assay and SP200 Automation Instrument along with the Thermo Scientific™ Orbitrap™ Astral™ mass spectrometer, this is the first large-scale plasma proteomics initiative of its kind to leverage mass spectrometry and AI-driven analytics to enhance early cancer detection and improve patient outcomes. Seer's latest platform advances will allow deep, unbiased proteomic analysis of 20,000 plasma samples in less time and cost than has ever before been possible. These will include samples from 15,000 cancer patients and 5,000 healthy patients that will serve as controls, sourced from Korea's leading cancer institutions: Seoul National University Hospital, the National Cancer Center, and Samsung Medical Center. The three-year study is funded by the K-Health MIRAE initiative under the Ministry of Health and Welfare, Republic of Korea, which supports ambitious, high-impact health research. 'We carefully evaluated multiple approaches to expand the dynamic range of the plasma proteome—including some attempting to replicate Seer's Proteograph platform—and Seer's assay stood out as the only solution capable of delivering the depth, scale, and, critically, reproducibility needed for this ambitious study,' said Professor Sang-Won Lee at the Center of Proteogenome Research (CPGR) of Korea University. 'The unique combination of Seer's latest platform and CPGR's proprietary dual online liquid chromatography technology gives us the ability to conduct population-scale research that would otherwise be prohibitively complex and slow. This collaboration represents a major step toward developing AI-powered diagnostics that could fundamentally improve how we detect and treat cancer in younger adults.' By leveraging the power of deep proteomic analysis, this study aims to catalyze a new wave of diagnostics that are more sensitive, scalable, and personalized—ultimately driving earlier interventions and improving survival outcomes in young adult cancer patients worldwide. Transformational Technology for Population-Scale Proteomics At the heart of the study is Seer's Proteograph ONE workflow, introduced this week at the 2025 American Society for Mass Spectrometry (ASMS) Conference in Baltimore, MD. The next-generation system dramatically increases scale and efficiency in proteomic analysis by: Processing 1,000+ samples per week per instrument Requiring only a single mass spectrometry injection per sample Completing 80-sample batches with <5 hours automated runtime Identifying up to 10 times more proteins than conventional mass spectrometry methods 'Korea University selected Seer's new Proteograph ONE workflow as the foundation for this critical and forward-looking initiative so that they can unlock the full potential of proteomics in population-scale research,' said Omid Farokhzad, Chair and CEO of Seer. 'We're excited to help define a new generation of diagnostics that can transform how diseases like cancer are detected and managed around the world.' The study also employs Thermo Scientific's Orbitrap Astral MS—the industry's leading mass spectrometer for proteomic research. The Proteograph offerings combined with the Orbitrap Astral MS provide a deep, full-range plasma proteome analysis at faster speeds to enable critical breakthrough discoveries in large-population studies. 'When it comes to plasma proteomics studies such as this, the Orbitrap Astral MS and Proteograph ONE workflow provide a powerful solution to drive groundbreaking research,' said Dan Shine, senior vice president and president of analytical instruments, Thermo Fisher Scientific. 'We're proud to be a part of initiatives like this to enable earlier detection and help progress precision medicine.' The next-generation offerings mark a significant evolution of the Proteograph Product Suite, delivering the scale, speed, and efficiency required to make population-level proteomics both practical and accessible. The collaboration with Korea University exemplifies the real-world impact of this technology—demonstrating how deep, unbiased proteomic insights powered by Seer's platform can now inform large-scale studies, accelerate biomarker discovery, and drive the development of AI-enabled diagnostics that redefine precision medicine. About Seer, Inc. Seer, Inc. (Nasdaq: SEER) sets the standard in deep, unbiased proteomics—delivering insights with a scale, speed, precision, and reproducibility previously unattainable. Seer's Proteograph Product Suite uniquely integrates proprietary engineered nanoparticles, streamlined automation instrumentation, optimized consumables, and advanced analytical software to solve challenges conventional methods have failed to overcome. Traditional proteomic technologies have struggled with inconsistent data, limited throughput, and prohibitive complexity, but Seer's robust and scalable workflow consistently reveals biological insights that others cannot. Seer's products are for research use only and are not intended for diagnostic procedures. For more information about Seer's differentiated approach and ongoing leadership in proteomics, visit Media Contact: Consort Partners [email protected] Investor Contact: Carrie Mendivil [email protected] Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
